Reactive metabolites in the biotransformation of molecules containing a furan ring

Chemical Research in Toxicology

Volumn 26, Issue 1, 2013, Pages 6-25

  Peterson, Lisa A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLFURAN; 3 [6 [7 CYANO 5 (3 FURYL) 2 NAPHTHOXYMETHYL] 2 PYRIDYL] 3 HYDROXY 6,8 DIOXABICYCLO[3.2.1]OCTANE; 3 METHYLFURAN; 4 IPOMEANOL; ANTIRETROVIRUS AGENT; BERGAMOTTIN; DITERPENOID; EPOXIDE; FURAN DERIVATIVE; FUROSEMIDE; GLUTATHIONE; L 754394; MENTHOFURAN; N [2 HYDROXY 1 INDAN YL] 5 [2 [[(1,1 DIMETHYLETHYL)AMINO]CARBONYL] 4 [(FURO[2,3 B]PYRIDIN 5 YL)METHYL]PIPERAZIN 1 YL] 4 HYDROXY 2 (PHENYLMETHYL)PENTANAMIDE; PRAZOSIN; TEUCRIN A; UNCLASSIFIED DRUG;

BIOTRANSFORMATION; CATALYSIS; CONJUGATION; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; DRUG MEGADOSE; EDEMA; HUMAN; HYPERSENSITIVITY; HYPERTENSION; JAUNDICE; LIVER CELL; LIVER MICROSOME; LIVER TOXICITY; METABOLITE; NONHUMAN; OXIDATION; POSTTRAUMATIC STRESS DISORDER; REVIEW; SINGLE DRUG DOSE;

ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; FURANS; GLUTATHIONE; MICROSOMES, LIVER; OXIDATION-REDUCTION;

EID: 84872541214     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx3003824     Document Type: Review

References (167)

1. Burka, L. T. and Boyd, M. R. (1985) Furans, in Bioactivation of Foreign Compounds, pp 243-257, Academic Press, New York.
2. Williams, G. M., Mattia, A., and Renwick, A. (2009) Furan-substituted aliphatic hydrocarbons, alchohols, aldehydes, ketones, carboxylic acids and related esters, sulfides, disulfides and ethers (addendums) WHO Food Addit. Ser. 60, 481-532
3. Zhou, S., Koh, H. L., Gao, Y., Gong, Z. Y., and Lee, E. J. (2004) Herbal bioactivation: the good, the bad and the ugly Life Sci. 74, 935-968
4. Saunders, R. A., Griffith, J. R., and Saalfield, F. E. (1974) Identification of some organic smog components based on rain water analysis Biomed. Mass Spectrom. 1, 192-194
5. Sunesson, A. L., Vaes, W. H. J., Nilsson, C. A., Blomquist, G., Andersson, B., and Carlson, R. (1995) Identification of volatile metabolites from five fungal species cultivated on two media Appl. Environ. Microbiol. 61, 2911-2918
6. Dalvie, D. K., Kalgutkar, A. S., Khojasteh-Bakht, S. C., Obach, R. S., and O'Donnell, J. P. (2002) Biotransformation reactions of five-membered aromatic heterocyclic rings Chem. Res. Toxicol. 15, 269-299
7. Kalgutkar, A. S., Gardner, I., Obach, R. S., Shaffer, C. L., Callegari, E., Henne, K. R., Mutlib, A. E., Dalvie, D. K., Lee, J. S., Nakai, Y., O'Donnell, J. P., Boer, J., and Harriman, S. P. (2005) A comprehensive listing of bioactivation pathways of organic functional groups Curr. Drug Metab. 6, 161-225
8. Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., and Aleo, M. D. (2011) Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States Chem. Res. Toxicol. 24, 1345-1410
9. Guengerich, F. P. (2003) Cytochrome P450 oxidations in the generation of reactive electrophiles: epoxidation and related reactions Arch. Biochem. Biophys. 409, 59-71
10. Ravindranath, V., Burka, L. T., and Boyd, M. R. (1984) Reactive metabolites from the bioactivation of toxic methylfurans Science 224, 884-886
11. Adger, B. M., Barrett, C., Brennan, J., McKervey, M. A., and Murray, R. W. (1991) Oxidation of furans with dimethyldioxirane J. Chem. Soc., Chem. Comm. 1553-1554
12. Ruzo, L. O., Casida, J. E., and Holden, I. (1985) Direct NMR detection of an epoxyfuran intermediate in peracid oxidation of the fungicide methfuroxam J. Chem. Soc., Chem. Commun. 1642-1643
13. Oishi, S. and Nelson, S. D. (1992) Evidence for the formation of heterocyclic arene oxides and a γ-keto enal by reaction of menthofuran with dimethyldioxirane JOC 57, 2744-2747
14. Chen, L. J., Hecht, S. S., and Peterson, L. A. (1995) Identification of cis -2-butene-1,4-dial as a microsomal metabolite of furan Chem. Res. Toxicol. 8, 903-906
15. Druckova, A. and Marnett, L. J. (2006) Characterization of the amino acid adducts of the enedial derivative of teucrin A Chem. Res. Toxicol. 19, 1330-1340
16. Wirth, P. J., Bettis, P. J., and Nelson, W. L. (1975) Microsomal metabolism of furosemide evidence for the nature of the reactive intermediate involved in covalent binding Mol. Pharmacol. 12, 759-768
17. Boyd, M. R., Burka, L. T., Wilson, B. J., and Sasame, H. A. (1978) In vitro studies on the metabolic activation of the pulmonary toxin, 4-ipomeanol, by rat lung and liver microsomes JPET 207, 677-686
18. Guengerich, F. P. (1977) Studies on the activation of a model furan compound: toxicity and covalent binding of 2-(N -ethyl-carbamoylhydroxymethyl) furan Biochem. Pharmacol. 26, 1909-1915
19. Erve, J. C., Vashishtha, S. C., DeMaio, W., and Talaat, R. E. (2007) Metabolism of prazosin in rat, dog, and human liver microsomes and cryopreserved rat and human hepatocytes and characterization of metabolites by liquid chromatography/tandem mass spectrometry Drug Metab. Dispos. 35, 908-916
20. International Agency for Research on Cancer (1995) Furan, in Dry Cleaning, Some Chlorinated Solvents and Other Industrial Chemicals, p 393, IARC, Lyon, France.
21. 4 and its distribution in air Clin. Toxicol. 6, 109-124
22. Maga, J. (1979) Furans in foods Crit. Rev. Food Sci. Nutr. 11, 355-366
23. Vranová, J. and Ciesarová, Z. (2009) Furan in food: a review Czech J. Food Sci. 27, 1-10
24. Food and Drug Administration. ((2009) Exploratory data on furan in food: individual food products, http://www.fda.gov/Food/FoodSafety/ FoodContaminantsAdulteration/ChemicalContaminants/Furan/ucm078439.htm.
25. National Toxicology Program (1993) Toxicology and Carcinogenesis Studies of Furan in F344/N Rats and B6C3F1 Mice, NTP Technical Report No. 402, US Department of Health and Human Services, Public Health Service, National Institutes of Health, Research Triangle Park, NC.
26. National Toxicology Program (2011) 12th Report on Carcinogens, US Department of Health and Human Services, Washington DC.
27. Mortelmans, K., Haworth, S., Lawlor, T., Speck, W., Tainer, B., and Zeiger, E. (1986) Salmonella mutagenicity tests. II. Results from the testing of 270 chemicals Environ. Mutagen. 7 (Suppl.) 1-119
28. Kellert, M., Brink, A., Richter, I., Schlatter, J., and Lutz, W. K. (2008) Tests for genotoxicity and mutagenicity of furan and its metabolite cis -2-butene-1,4-dial in L5178Y tk± mouse lymphoma cells Mutat. Res. 657, 127-132
29. McDaniel, L. P., Ding, W., Dobrovolsky, V. N., Shaddock, J. G., Jr., Mittelstaedt, R. A., Doerge, D. R., and Heflich, R. H. (2012) Genotoxicity of furan in Big Blue rats Mutat. Res. 742, 72-78
30. Wilson, D. M., Goldsworthy, T. L., Popp, J. A., and Butterworth, B. E. (1992) Evaluation of genotoxicity, pathological lesions, and cell proliferation in livers of rats and mice treated with furan Environ. Mol. Mutagen. 19, 209-222
31. Melnick, R. L. and Huff, J. (1993) Liver carcinogenesis is not a predicted outcome of chemically induced hepatocyte proliferation Toxicol. Ind. Health 9, 415-438
32. Melnick, R. L., Kohn, M. C., and Portier, C. J. (1996) Implications for risk assessment of suggested nongenotoxic mechanisms of chemical carcinogenesis Environ. Health Perspect. 104 (Suppl. 1) 123-134
33. Reynolds, S. H., Stowers, S. J., Patterson, R. M., Maronpot, R. R., Aaronson, S. A., and Anderson, M. W. (1987) Activated oncogenes in B6C3F1 mouse liver tumors: Implications for risk assessment Science 237, 1309-1316
34. Neuwirth, C., Mosesso, P., Pepe, G., Fiore, M., Malfatti, M., Turteltaub, K., Dekant, W., and Mally, A. (2012) Furan carcinogenicity: DNA binding and genotoxicity of furan in rats in vivo Mol. Nutr. Food Res. 56, 1363-1374
35. Ding, W., Petibone, D. M., Latendresse, J. R., Pearce, M. G., Muskhelishvili, L., White, G. A., Chang, C. W., Mittelstaedt, R. A., Shaddock, J. G., McDaniel, L. P., Doerge, D. R., Morris, S. M., Bishop, M. E., Manjanatha, M. G., Aidoo, A., and Heflich, R. H. (2012) In vivo genotoxicity of furan in F344 rats at cancer bioassay doses Toxicol. Appl. Pharmacol. 261, 164-171
36. Peterson, L. A., Naruko, K. C., and Predecki, D. (2000) A reactive metabolite of furan cis -2-butene-1,4-dial, is mutagenic in the Ames assay Chem. Res. Toxicol. 13, 531-534
37. Gingipalli, L. and Dedon, P. C. (2001) Reaction of cis-and trans -2-butene-1,4-dial with 2′-deoxycytidine to form stable oxadiazabicyclooctaimine adducts J. Am. Chem. Soc. 123, 2664-2665
38. Byrns, M. C., Predecki, D. P., and Peterson, L. A. (2002) Characterization of nucleoside adducts of cis -2-butene-1,4-dial, a reactive metabolite of furan Chem. Res. Toxicol. 15, 373-379
39. 2-etheno-2′-deoxyguanosine adducts by cis- 2-butene-1,4-dial, a reactive metabolite of furan Chem. Res. Toxicol. 17, 1607-1613
40. Byrns, M. C., Vu, C. C., Neidigh, J. W., Abad, J. L., Jones, R. A., and Peterson, L. A. (2006) Detection of DNA adducts derived from the reactive metabolite of furan cis -2-butene-1,4-dial Chem. Res. Toxicol. 19, 414-420
41. Moser, G. J., Foley, J., Burnett, M., Goldsworthy, T. L., and Maronpot, R. (2009) Furan-induced dose-response relationships for liver cytotoxicity, cell proliferation, and tumorigenicity (furan-induced liver tumorigenicity) Exp. Toxicol. Pathol. 61, 101-111
42. Gill, S., Bondy, G., Lefebvre, D. E., Becalski, A., Kavanagh, M., Hou, Y., Turcotte, A. M., Barker, M., Weld, M., Vavasour, E., and Cooke, G. M. (2010) Subchronic oral toxicity study of furan in Fischer-344 rats Toxicol. Pathol. 38, 619-630
43. Gill, S., Kavanagh, M., Barker, M., Weld, M., Vavasour, E., Hou, Y., and Cooke, G. M. (2011) Subchronic oral toxicity study of furan in B6C3F1 mice Toxicol. Pathol. 39, 787-794
44. Moro, S., Chipman, J. K., Antczak, P., Turan, N., Dekant, W., Falciani, F., and Mally, A. (2012) Identification and pathway mapping of furan target proteins reveal mitochondrial energy production and redox regulation as critical targets of furan toxicity Toxicol. Sci. 126, 336-352
45. Fransson-Steen, R., Goldsworthy, T. L., Kedderis, G. L., and Maronpot, R. R. (1997) Furan-induced liver cell proliferation and apoptosis in female B6C3F1 mice Toxicology 118, 195-204
46. Sirica, A. E. (1996) Biliary proliferation and adaptation in furan-induced rat liver injury and carcinogenesis Toxicol. Pathol. 24, 90-99
47. Hamadeh, H. K., Jayadev, S., Gaillard, E. T., Huang, Q., Stoll, R., Blanchard, K., Chou, J., Tucker, C. J., Collins, J., Maronpot, R., Bushel, P., and Afshari, C. A. (2004) Integration of clinical and gene expression endpoints to explore furan-mediated hepatotoxicity Mutat. Res. 549, 169-183
48. Hickling, K. C., Hitchcock, J. M., Oreffo, V., Mally, A., Hammond, T. G., Evans, J. G., and Chipman, J. K. (2010) Evidence of oxidative stress and associated DNA damage, increased proliferative drive, and altered gene expression in rat liver produced by the cholangiocarcinogenic agent furan Toxicol. Pathol. 38, 230-243
49. Chen, T., Mally, A., Ozden, S., and Chipman, J. K. (2010) Low doses of the carcinogen furan alter cell cycle and apoptosis gene expression in rat liver independent of DNA methylation Environ. Health Perspect. 118, 1597-1602
50. Hickling, K. C., Hitchcock, J. M., Chipman, J. K., Hammond, T. G., and Evans, J. G. (2010) Induction and progression of cholangiofibrosis in rat liver injured by oral administration of furan Toxicol. Pathol. 38, 213-229
51. 14C]furan in the male F344 rat J. Toxicol. Environ. Health 34, 245-257
52. Parmar, D. and Burka, L. T. (1993) Studies on the interaction of furan with hepatic cytochrome P-450 J. Biochem. Toxicol. 8, 1-9
53. Carfagna, M. A., Held, S. D., and Kedderis, G. L. (1993) Furan-induced cytolethality in isolated rat hepatocytes: Correspondence with in vivo dosimetry Toxicol. Appl. Pharmacol. 123, 265-273
54. Mugford, C. A., Carfagna, M. A., and Kedderis, G. L. (1997) Furan-mediated uncoupling of hepatic oxidative phosphorylation in Fischer-344 rats: an early event in cell death Toxicol. Appl. Pharmacol. 144, 1-11
55. Kedderis, G. L., Carfagna, M. A., Held, S. D., Batra, R., Murphy, J. E., and Gargas, M. L. (1993) Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro Toxicol. Appl. Pharmacol. 123, 274-282
56. Chen, L. J., Hecht, S. S., and Peterson, L. A. (1997) Characterization of amino acid and glutathione adducts of cis -2-butene-1,4-dial, a reactive metabolite of furan Chem. Res. Toxicol. 10, 866-874
57. Peterson, L. A., Cummings, M. E., Vu, C. C., and Matter, B. A. (2005) Glutathione trapping to measure microsomal oxidation of furan to cis -2-butene-1,4-dial Drug Metab. Dispos. 33, 1453-1458
58. Gates, L. A., Lu, D., and Peterson, L. A. (2012) Trapping of cis -2-butene-1,4-dial to measure furan metabolism in human liver microsomes by cytochrome P450 enzymes Drug Metab. Dispos. 40, 596-601
59. Peterson, L. A., Cummings, M. E., Chan, J. Y., Vu, C. C., and Matter, B. A. (2006) Identification of a cis -2-butene-1,4-dial-derived glutathione conjugate in the urine of furan-treated rats Chem. Res. Toxicol. 19, 1138-1141
60. Kellert, M., Wagner, S., Lutz, U., and Lutz, W. K. (2008) Biomarkers of furan exposure by metabolic profiling of rat urine with liquid chromatography-tandem mass spectrometry and principal component analysis Chem. Res. Toxicol. 21, 761-768
61. Lu, D., Sullivan, M. M., Phillips, M. B., and Peterson, L. A. (2009) Degraded protein adducts of cis -2-butene-1,4-dial are urinary and hepatocyte metabolites of furan Chem. Res. Toxicol. 22, 997-1007
62. Lu, D. and Peterson, L. A. (2010) Identification of furan metabolites derived from cysteine- cis -2-butene-1,4-dial-lysine cross-links Chem. Res. Toxicol. 23, 142-151
63. Peterson, L. A., Phillips, M. B., Lu, D., and Sullivan, M. M. (2011) Polyamines are traps for reactive intermediates in furan metabolism Chem. Res. Toxicol. 24, 1924-1936
64. Hamberger, C., Kellert, M., Schauer, U. M., Dekant, W., and Mally, A. (2010) Hepatobiliary toxicity of furan: identification of furan metabolites in bile of male F344/N rats Drug Metab. Dispos. 38, 1698-1706
65. Byrns, M. C. (2005) Determination of the Role of DNA Alkylation by cis -2-Butene-1,4-dial in Furan-Induced Carcinogenesis, Ph.D. Thesis, University of Minnesota, Minneapolis, MN.
66. Newsome, J. R., Norman, V., and Keith, C. H. (1965) Vapor phase analysis of tobacco smoke Tob. Int. 9, 102-110
67. Ravindranath, V., McMenamin, M. G., Dees, J. H., and Boyd, M. R. (1986) 2-Methylfuran toxicity in rats-Role of metabolic activation in vivo Toxicol. Appl. Pharmacol. 85, 78-91
68. Ravindranath, V. and Boyd, M. R. (1985) Metabolic activation of 2-methylfuran by rat microsomal systems Toxicol. Appl. Pharmacol. 78, 370-376
69. Ravindranath, V. and Boyd, M. R. (1991) Effect of modulations of glutathione synthesis on the hepatotoxicity of 2-methylfuran Biochem. Pharmacol. 41, 1311-1318
70. 2-ethenodeoxyguanosine adduct Chem. Res. Toxicol. 5, 706-712
71. Liu, Z., Young-Sciame, R., and Hecht, S. S. (1996) Liquid chromatography-electrospray ionization mass spectrometric detection of an ethenodeoxyguanosine adduct and its hemiaminal precursors in DNA reacted with α-acetoxy- N -nitrosopiperdine and cis -4-oxo-2-pentenal Chem. Res. Toxicol. 9, 774-780
72. Noce, R., Paredes, B. E., Pichler, W. J., and Krahenbuhl, S. (2000) Acute generalized exanthematic pustulosis (AGEP) in a patient treated with furosemide Am. J. Med. Sci. 320, 331-333
73. Dargie, H. J. and Dollery, C. T. (1975) Adverse Reactions to Diuretic Drugs, in Meyler's Side Effects of Drugs (Dukes, M. N. G., Ed.) p 483, Exerpta Medica, Amsterdam, The Netherlands.
74. Mitchell, J. R., Potter, W. Z., Hinson, J. A., and Jollow, D. J. (1974) Hepatic necrosis caused by furosemide Nature 251, 508-511
75. Williams, D. P., Antoine, D. J., Butler, P. J., Jones, R., Randle, L., Payne, A., Howard, M., Gardner, I., Blagg, J., and Park, B. K. (2007) The metabolism and toxicity of furosemide in the Wistar rat and CD-1 mouse: a chemical and biochemical definition of the toxicophore J. Pharmacol. Exp. Ther. 322, 1208-1220
76. Mitchell, J. R., Nelson, W. L., Potter, W. Z., Sasame, H. A., and Jollow, D. J. (1976) Metabolic activation of furosemide to a chemically reactive, hepatotoxic metabolite J. Pharmacol. Exp. Ther. 199, 41-52
77. Wong, S. G., Card, J. W., and Racz, W. J. (2000) The role of mitochondrial injury in bromobenzene and furosemide induced hepatotoxicity Toxicol. Lett. 116, 171-181
78. Massey, T. E., Walker, R. M., McElligott, T. F., and Racz, W. J. (1987) Furosemide toxicity in isolated mouse hepatocyte suspensions Toxicology 43, 149-160
79. Grewal, K. K., Rafeiro, E., and Racz, W. J. (1996) Bromobenzene and furosemide hepatotoxicity: alterations in glutathione, protein thiols, and calcium Can. J. Physiol. Pharmacol. 74, 257-264
80. Masubuchi, N., Makino, C., and Murayama, N. (2007) Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans Chem. Res. Toxicol. 20, 455-464
81. Chen, L. J. and Burka, L. T. (2007) Chemical and enzymatic oxidation of furosemide: formation of pyridinium salts Chem. Res. Toxicol. 20, 1741-1744
82. Yang, K. H., Choi, Y. H., Lee, U., Lee, J. H., and Lee, M. G. (2009) Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism J. Pharm. Pharmacol. 61, 47-54
83. Nakahama, H., Miwa, Y., Yamaji, A., Orita, Y., Fukuhara, Y., Yanase, M., Kamada, T., Sonoda, T., Ishibasi, M., and Ichikawa, Y. (1987) The urinary excretion of frusemide and its metabolites by kidney transplant patients Eur. J. Clin. Pharmacol. 32, 313-315
84. Beermann, B., Dalen, E., Lindstrom, B., and Rosen, A. (1975) On the fate of furosemide in man Eur. J. Clin. Pharmacol. 9, 51-61
85. Perez, J., Sitar, D. S., and Ogilvie, R. I. (1979) Biotransformation of furosemide in patients with acute pulmonary edema Drug Metab. Dispos. 7, 383-387
86. Erve, J. C., Vashishtha, S. C., Ojewoye, O., Adedoyin, A., Espina, R., DeMaio, W., and Talaat, R. E. (2008) Metabolism of prazosin in rat and characterization of metabolites in plasma, urine, faeces, brain and bile using liquid chromatography/mass spectrometry (LC/MS) Xenobiotica 38, 540-558
87. Amunom, I., Dieter, L. J., Tamasi, V., Cai, J., Conklin, D. J., Srivastava, S., Martin, M. V., Guengerich, F. P., and Prough, R. A. (2011) Cytochromes P450 catalyze the reduction of α,β-unsaturated aldehydes Chem. Res. Toxicol. 24, 1223-1230
88. Becalski, A., Hayward, S., Krakalovich, T., Pelletier, L., Roscoe, V., and Vavasour, E. (2010) Development of an analytical method and survey of foods for furan, 2-methylfuran and 3-methylfuran with estimated exposure Food Addit. Contam., Part A 27, 764-775
89. Gordon, S. M., Wallace, L. A., Brinkman, M. C., Callahan, P. J., and Kenny, D. V. (2002) Volatile organic compounds as breath biomarkers for active and passive smoking Environ. Health Perspect. 110, 689-698
90. Buszewski, B., Ulanowska, A., Ligor, T., Denderz, N., and Amann, A. (2009) Analysis of exhaled breath from smokers, passive smokers and non-smokers by solid-phase microextraction gas chromatography/mass spectrometry Biomed. Chromatogr. 23, 551-556
91. Haschek, W. M., Morse, C. C., Boyd, M. R., Hakkinen, P. J., and Witschi, H. P. (1983) Pathology of acute inhalation exposure to 3-methylfuran in the rat and hamster Exp. Mol. Pathol. 39, 342-354
92. Morse, C. C., Boyd, M. R., and Witschi, H. (1984) The effect of 3-methylfuran inhalation exposure on the rat nasal cavity Toxicology 30, 195-204
93. Haschek, W. M., Boyd, M. R., Hakkinen, P. J., Owenby, C. S., and Witschi, H. (1984) Acute inhalation toxicity of 3-methylfuran in the mouse: pathology, cell kinetics, and respiratory rate effects Toxicol. Appl. Pharmacol. 72, 124-133
94. Gammal, L. M., Wiley, R. A., Traiger, G., Haschek, W. M., and Baraban, S. (1984) Toxicity-distribution relationships among 3-alkylfurans in the mouse lung Toxicology 30, 177-184
95. Wiley, R. A., Traiger, G. J., Baraban, S., and Gammal, L. M. (1984) Toxicity-distribution relationships among 3-alkylfurans in mouse liver and kidney Toxicol. Appl. Pharmacol. 74, 1-9
96. Witschi, H. P., Tryka, A. F., Mauderly, J. L., Haschek, W. M., Satterfield, L. C., Bowles, N. D., and Boyd, M. R. (1985) Long-term effects of repeated exposure to 3-methylfuran in hamsters and mice J. Toxicol. Environ. Health 16, 581-592
97. Boyd, M. R., Statham, C. N., Franklin, R. B., and Mitchell, J. R. (1978) Pulmonary bronchiolar alkylation and necrosis by 3-methylfuran, a naturally occurring potential atmospheric contaminant Nature 272, 270-271
98. Boyd, M. R., Burka, L. T., Harris, T. M., and Wilson, B. J. (1974) Lung-toxic furanoterpenoids produced by sweet potatoes (Ipomoea batatas) following microbial infection Biochim. Biophys. Acta 337, 184-195
99. Chen, L. J., DeRose, E. F., and Burka, L. T. (2006) Metabolism of furans in vitro: ipomeanine and 4-ipomeanol Chem. Res. Toxicol. 19, 1320-1329
100. Boyd, M. R. and Burka, L. T. (1978) In vivo studies on the relationship between target organ alkylation and the pulmonary toxicity of a chemically reactive metabolite of 4-ipomeanol J. Pharmacol. Exp. Ther. 207, 687-697
101. Durham, S. K., Boyd, M. R., and Castleman, W. L. (1985) Pulmonary endothelial and bronchiolar epithelial lesions induced by 4-ipomeanol in mice Am. J. Pathol. 118, 66-75
102. Rowinsky, E. K., Noe, D. A., Ettinger, D. S., Christian, M. C., Lubejko, B. G., Fishman, E. K., Sartorius, S. E., Boyd, M. R., and Donehower, R. C. (1993) Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans Cancer Res. 53, 1794-1801
103. Kasturi, V. K., Dearing, M. P., Piscitelli, S. C., Russell, E. K., Sladek, G. G., O'Neil, K., Turner, G. A., Morton, T. L., Christian, M. C., Johnson, B. E., and Kelley, M. J. (1998) Phase I study of a five-day dose schedule of 4-ipomeanol in patients with non-small cell lung cancer Clin. Cancer Res. 4, 2095-2102
104. Lakhanpal, S., Donehower, R. C., and Rowinsky, E. K. (2001) Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma Invest. New Drugs 19, 69-76
105. Boyd, M. R., Sasame, H. A., and Franklin, R. B. (1980) Comparison of ratios of covalent binding to total metabolism of the pulmonary toxin, 4-ipomeanol, in vitro in pulmonary and hepatic microsomes, and the effects of pretreatments with phenobarbital or 3-methylcholanthrene Biochem. Biophys. Res. Commun. 93, 1167-1172
106. Czerwinski, M., McLemore, T. L., Philpot, R. M., Nhamburo, P. T., Korzekwa, K., Gelboin, H. V., and Gonzalez, F. J. (1991) Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism Cancer Res. 51, 4636-4638
107. Verschoyle, R. D., Philpot, R. M., Wolf, C. R., and Dinsdale, D. (1993) CYP4B1 activates 4-ipomeanol in rat lung Toxicol. Appl. Pharmacol. 123, 193-198
108. Baer, B. R., Rettie, A. E., and Henne, K. R. (2005) Bioactivation of 4-ipomeanol by CYP4B1: Adduct characterization and evidence for an enedial intermediate Chem. Res. Toxicol. 18, 855-864
109. Zheng, Y. M., Fisher, M. B., Yokotani, N., Fujii-Kuriyama, Y., and Rettie, A. E. (1998) Identification of a meander region proline residue critical for heme binding to cytochrome P450: implications for the catalytic function of human CYP4B1 Biochemistry 37, 12847-12851
110. Hukkanen, J., Pelkonen, O., Hakkola, J., and Raunio, H. (2002) Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung Crit. Rev. Toxicol. 32, 391-411
111. Statham, C. N. and Boyd, M. R. (1982) Effects of phenobarbitol and 3-methylcholanthrene on the in vivo distribution, metabolism and covalent binding of 4-ipomeanol in the rat; implications for target organ toxicity Biochem. Pharmacol. 31, 3973-3977
112. Buckpitt, A. R. and Boyd, M. R. (1980) The in vitro formation of glutathione conjugates with the microsomally activated pulmonary bronchiolar alkylating agent and cytotoxin, 4-ipomeanol JPET 215, 97-103
113. Alvarez-Diez, T. M. and Zheng, J. (2004) Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol Chem. Res. Toxicol. 17, 150-157
114. Alvarez-Diez, T. M. and Zheng, J. (2004) Detection of glutathione conjugates derived from 4-ipomeanol metabolism in bile of rats by liquid chromatography-tandem mass spectrometry Drug Metab. Dispos. 32, 1345-1350
115. Wolf, C. R., Statham, C. N., McMenamin, M. G., Bend, J. R., Boyd, M. R., and Philpot, R. M. (1982) The relationship between the catalytic activities of rabbit pulmonary cytochrome P-450 isozymes and the lung-specific toxicity of the furan derivative, 4-ipomeanol Mol. Pharmacol. 22, 738-744
116. Zhang, K. E., Naue, J. A., Arison, B., and Vyas, K. P. (1996) Microsomal metabolism of the 5-lipoxygenase inhibitor L-739,010: Evidence for furan bioactivation Chem. Res. Toxicol. 9, 547-554
117. Molon-Noblot, S., Gillet, J. P., Durand-Cavagna, G., Huber, A. C., Patrick, D. H., and Duprat, P. (1996) Lipidosis induced in the dog gallbladder by a direct 5-lipoxygenase inhibitor Toxicol. Pathol. 24, 231-237
118. Chauret, N., Nicoll-Griffith, D., Friesen, R., Li, C., Trimble, L., Dube, D., Fortin, R., Girard, Y., and Yergey, J. (1995) Microsomal metabolism of the 5-lipoxygenase inhibitors L-746,530 and L-739,010 to reactive intermediates that covalently bind to protein: the role of the 6,8-dioxabicyclo[3.2.1]octanyl moiety Drug Metab. Dispos. 23, 1325-1334
119. Eagling, V. A., Tjia, J. F., and Back, D. J. (1998) Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes Br. J. Clin. Pharmacol. 45, 107-114
120. Larrey, D., Vial, T., Pauwels, A., Castot, A., Biour, M., David, M., and Michel, H. (1992) Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity Ann. Intern. Med. 117, 129-132
121. Pauwels, A., Thierman-Duffaud, D., Azanowsky, J. M., Loiseau, D., Biour, M., and Levy, V. G. (1992) Acute hepatitis caused by wild germander. Hepatotoxicity of herbal remedies. Two cases Gastroenterol. Clin. Biol. 16, 92-95
122. Mostefa-Kara, N., Pauwels, A., Pines, E., Biour, M., and Levy, V. G. (1992) Fatal hepatitis after herbal tea Lancet 340, 674
123. Mattei, A., Bizollon, T., Charles, J. D., Debat, P., Fontanges, T., Chevallier, M., and Trepo, C. (1992) Liver damage induced by the ingestion of a product of phytotherapy containing wild germander. Four cases Gastroenterol. Clin. Biol. 16, 798-800
124. Legoux, J. L., Maitre, F., Labarriere, D., Gargot, D., Festin, D., and Causse, X. (1992) Cytolytic hepatitis and wild Germander: a new case with reintroduction Gastroenterol. Clin. Biol. 16, 813-815
125. Castot, A. and Larrey, D. (1992) Hepatitis observed during a treatment with a drug or tea containing Wild Germander. Evaluation of 26 cases reported to the Regional Centers of Pharmacovigilance Gastroenterol. Clin. Biol. 16, 916-922
126. Diaz, D., Ferroudji, S., Heran, B., Barneon, G., Larrey, D., and Michel, H. (1992) Fulminant hepatitis caused by wild germander Gastroenterol. Clin. Biol. 16, 1006-1007
127. Ben Yahia, M., Mavier, P., Metreau, J. M., Zafrani, E. S., Fabre, M., Gatineau-Saillant, G., Dhumeaux, D., and Mallat, A. (1993) Chronic active hepatitis and cirrhosis induced by wild germander. 3 Cases Gastroenterol. Clin. Biol. 17, 959-962
128. Loeper, J., Descatoire, V., Letteron, P., Moulis, C., Degott, C., Dansette, P., Fau, D., and Pessayre, D. (1994) Hepatotoxicity of germander in mice Gastroenterology 106, 464-472
129. Kouzi, S. A., McMurtry, R. J., and Nelson, S. D. (1994) Hepatotoxicity of germander (Teucrium chamaedrys L.) and one of its constituent neoclerodane diterpenes teucrin A in the mouse Chem. Res. Toxicol. 7, 850-856
130. Lekehal, M., Pessayre, D., Lereau, J. M., Moulis, C., Fouraste, I., and Fau, D. (1996) Hepatotoxicity of the herbal medicine germander: metabolic activation of its furano diterpenoids by cytochrome P450 3A depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes Hepatology 24, 212-218
131. De Berardinis, V., Moulis, C., Maurice, M., Beaune, P., Pessayre, D., Pompon, D., and Loeper, J. (2000) Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes Mol. Pharmacol. 58, 542-551
132. Druckova, A., Mernaugh, R. L., Ham, A. J., and Marnett, L. J. (2007) Identification of the protein targets of the reactive metabolite of teucrin A in vivo in the rat Chem. Res. Toxicol. 20, 1393-1408
133. Gordon, W. P., Forte, A. J., McMurtry, R. J., Gal, J., and Nelson, S. D. (1982) Hepatotoxicity and pulmonary toxicity of pennyroyal oil and its constituent terpenes in the mouse Toxicol. Appl. Pharmacol. 65, 413-424
134. Sullivan, J. B., Jr., Rumack, B. H., Thomas, H., Jr., Peterson, R. G., and Bryson, P. (1979) Pennyroyal oil poisoning and hepatotoxicity JAM 242, 2873-2874
135. Anderson, I. B., Mullen, W. H., Meeker, J. E., Khojasteh, B., Oishi, S., Nelson, S. D., and Blanc, P. D. (1996) Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature Ann. Intern. Med. 124, 726-734
136. Masada, Y. (1976) The Analysis of Essential Oils by Gas Chromatography and Mass Spectrometry, Wiley, New York.
137. Gordon, W. P., Huitric, A. C., Seth, C. L., McClanahan, R. H., and Nelson, S. D. (1987) The metabolism of the abortifacient terpene, (R)-(+)-pulegone, to a proximate toxin, menthofuran Drug Metab. Dispos. 15, 589-594
138. Thomassen, D., Slattery, J. T., and Nelson, S. D. (1988) Contribution of menthofuran to the hepatotoxicity of pulegone: assessment based on matched area under the curve and on matched time course J. Pharmacol. Exp. Ther. 244, 825-829
139. Moorthy, B., Madyastha, P., and Madyastha, K. M. (1989) Metabolism of a monoterpene ketone, R-(+)-pulegone - a hepatotoxin in rat Xenobiotica 19, 217-224
140. Thomassen, D., Knebel, N., Slattery, J. T., McClanahan, R. H., and Nelson, S. D. (1992) Reactive intermediates in the oxidation of menthofuran by cytochromes P-450 Chem. Res. Toxicol. 5, 123-130
141. Thomassen, D., Slattery, J. T., and Nelson, S. D. (1990) Menthofuran-dependent and independent aspects of pulegone hepatotoxicity: roles of glutathione J. Pharmacol. Exp. Ther. 253, 567-572
142. Madyastha, K. M. and Raj, C. P. (1994) Effects of menthofuran, a monoterpene furan on rat liver microsomal enzymes, in vivo Toxicology 89, 119-125
143. Madyastha, K. M. and Raj, C. P. (1990) Biotransformations of R-(+)-pulegone and menthofuran in vitro: chemical basis for toxicity Biochem. Biophys. Res. Commun. 173, 1086-1092
144. Madyastha, K. M. and Raj, C. P. (1992) Metabolic fate of menthofuran in rats. Novel oxidative pathways Drug Metab. Dispos. 20, 295-301
145. Khojasteh-Bakht, S. C., Chen, W., Koenigs, L. L., Peter, R. M., and Nelson, S. D. (1999) Metabolism of (R)-(+)-pulegone and (R)-(+)-menthofuran by human liver cytochrome P-450s: evidence for formation of a furan epoxide Drug Metab. Dispos. 27, 574-580
146. Khojasteh-Bakht, S. C., Koenigs, L. L., Peter, R. M., Trager, W. F., and Nelson, S. D. (1998) (R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6 Drug Metab. Dispos. 26, 701-704
147. Kramlinger, V. M., von Weymarn, L. B., and Murphy, S. E. (2012) Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, beta-nicotyrine and menthol Chem.-Biol. Interact. 197, 87-92
148. Chen, L. J., Lebetkin, E. H., and Burka, L. T. (2003) Metabolism of (R)-(+)-menthofuran in Fischer-344 rats: identification of sulfonic acid metabolites Drug Metab. Dispos. 31, 1208-1213
149. Khojasteh, S. C., Oishi, S., and Nelson, S. D. (2010) Metabolism and toxicity of menthofuran in rat liver slices and in rats Chem. Res. Toxicol. 23, 1824-1832
150. Madyastha, K. M. and Gaikwad, N. W. (1998) Metabolic fate of S-(-)-pulegone in rat Xenobiotica 28, 723-734
151. McClanahan, R. H., Thomassen, D., Slattery, J. T., and Nelson, S. D. (1989) Metabolic activation of (R)-(+)-pulegone to a reactive enonal that covalently binds to mouse liver proteins Chem. Res. Toxicol. 2, 349-355
152. Edwards, D. J., Bellevue, F. H., III, and Woster, P. M. (1996) Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice Drug Metab. Dispos. 24, 1287-1290
153. Schmiedlin-Ren, P., Edwards, D. J., Fitzsimmons, M. E., He, K., Lown, K. S., Woster, P. M., Rahman, A., Thummel, K. E., Fisher, J. M., Hollenberg, P. F., and Watkins, P. B. (1997) Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins Drug Metab. Dispos. 25, 1228-1233
154. He, K., Iyer, K. R., Hayes, R. N., Sinz, M. W., Woolf, T. F., and Hollenberg, P. F. (1998) Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice Chem. Res. Toxicol. 11, 252-259
155. Tassaneeyakul, W., Guo, L. Q., Fukuda, K., Ohta, T., and Yamazoe, Y. (2000) Inhibition selectivity of grapefruit juice components on human cytochromes P450 Arch. Biochem. Biophys. 378, 356-363
156. Guo, L. Q., Fukuda, K., Ohta, T., and Yamazoe, Y. (2000) Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity Drug Metab. Dispos. 28, 766-771
157. Wangensteen, H., Molden, E., Christensen, H., and Malterud, K. E. (2003) Identification of epoxybergamottin as a CYP3A4 inhibitor in grapefruit peel Eur. J. Clin. Pharmacol. 58, 663-668
158. Seden, K., Dickinson, L., Khoo, S., and Back, D. (2010) Grapefruit-drug interactions Drugs 70, 2373-2407
159. Lin, H. L., Kent, U. M., and Hollenberg, P. F. (2005) The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5 J. Pharmacol. Exp. Ther. 313, 154-164
160. Bumpus, N. N., Sridar, C., Kent, U. M., and Hollenberg, P. F. (2005) The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation Drug Metab. Dispos. 33, 795-802
161. Kent, U. M., Lin, H. L., Noon, K. R., Harris, D. L., and Hollenberg, P. F. (2006) Metabolism of bergamottin by cytochromes P450 2B6 and 3A5 J. Pharmacol. Exp. Ther. 318, 992-1005
162. Lin, J. H., Chiba, M., Chen, I. W., Vastag, K. J., Nishime, J. A., Dorsey, B. D., Michelson, S. R., and McDaniel, S. L. (1995) Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys J. Pharmacol. Exp. Ther. 274, 264-269
163. Chiba, M., Nishime, J. A., and Lin, J. H. (1995) Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor J. Pharmacol. Exp. Ther. 275, 1527-1534
164. Sahali-Sahly, Y., Balani, S. K., Lin, J. H., and Baillie, T. A. (1996) In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4 Chem. Res. Toxicol. 9, 1007-1012
165. Lightning, L. K., Jones, J. P., Friedberg, T., Pritchard, M. P., Shou, M., Rushmore, T. H., and Trager, W. F. (2000) Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394 Biochemistry 39, 4276-4287
166. Bateman, K. P., Baker, J., Wilke, M., Lee, J., Leriche, T., Seto, C., Day, S., Chauret, N., Ouellet, M., and Nicoll-Griffith, D. A. (2004) Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry Chem. Res. Toxicol. 17, 1356-1361
167. Böhme, A., Thaens, D., Schramm, F., Paschke, A., and Schüürmann, G. (2010) Thiol reactivity and its impact on the ciliate toxicity of α,β-unsaturated aldehydes, ketones, and esters Chem. Res. Toxicol. 23, 1905-1912